---
schema_version: "secwatch.filing_event.v1"
accession: "0001935979-23-000014"
form_type: "8-K"
ticker: "BHVN"
cik: "0001935979"
company_name: "Biohaven Ltd."
filed_at: "2023-03-23T23:59:59+00:00"
generated_at: "2026-06-17T19:32:36.713489+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Biohaven Q4 2022 net loss $201.1M; licenses TYK2/JAK1 inhibitor BHV-8000

## Summary
- Q4 2022 net loss $201.1M ($3.32/share); cash $465.3M at year-end, no debt.
- Acquired exclusive global ex-China rights to oral brain-penetrant TYK2/JAK1 inhibitor BHV-8000; Phase 1 start planned in 2023.
- Completed Phase 1 SAD/MAD for Kv7 activator BHV-7000; no sedation/dizziness/ataxia; plans EEG study H1 2023 and pivotal H2 2023.
- Appointed Bruce Car (CSO), Irfan Qureshi (CMO), Tanya Fischer (CDO) to management team.

## SEC filing metadata
- accession: 0001935979-23-000014
- form_type: 8-K
- ticker: BHVN
- cik: 0001935979
- company_name: Biohaven Ltd.
- filed_at: 2023-03-23T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1935979/000193597923000014/0001935979-23-000014-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1935979/000193597923000014/bhvn-20230323.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001935979-23-000014
- JSON: https://secwatch.observer/filing/0001935979-23-000014.json
- Plain text: https://secwatch.observer/filing/0001935979-23-000014.txt

## Key facts
- Earnings Releases
  Biohaven Ltd. reported financial results for fourth quarter and full year ended December 31, 2022.
  - Period: fourth quarter and full year ended December 31, 2022
  - Result: reported results
  source text: On March 23, 2023, Biohaven Ltd. (the " Registrant ") issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1935979/000193597923000014/0001935979-23-000014-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.